biostudies-literatureUnknown73Boudou-Rouquette PBaxter International<h4>Background</h4>Immune checkpoint inhibitors (ICI) are dramatically active in a minority of non-small cell lung cancer (NSCLC) patients. We studied here the relationship between patients's metabolism and outcome under ICI.<h4>Methods</h4>Metastatic NSCLC patients underwent a nutritional assessment prior to initiating immunotherapy. Resting energy expenditure (REE) was measured (mREE) using ambulatory indirect calorimetry and compared with the theoretical value (tREE) provided by the Harris and Benedict formula. The primary endpoint was 6-month progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and disease control rate (DCR) based on investigator review per RECIST v1.1. and overall survival (OS). The association of patient's metabolism with 6-montEBioMedicine103630https://www.ebi.ac.uk/biostudies/studies/S-EPMC8536532biostudies-literatureDevelopment and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.PMC8536532Alifano MDamotte DJouinot AFabre EArrondeau JDurand JPGervais CGiraud FGoldwasser FRassy NAlexandre JPiketty ACMansuet-Lupo ADe Percin SBoudou-Rouquette PVilleminey CVUlmann GWislez MfalseDevelopment and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.<h4>Background</h4>Immune checkpoint inhibitors (ICI) are dramatically active in a minority of non-small cell lung cancer (NSCLC) patients. We studied here the relationship between patients's metabolism and outcome under ICI.<h4>Methods</h4>Metastatic NSCLC patients underwent a nutritional assessment prior to initiating immunotherapy. Resting energy expenditure (REE) was measured (mREE) using ambulatory indirect calorimetry and compared with the theoretical value (tREE) provided by the Harris and Benedict formula. The primary endpoint was 6-month progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and disease control rate (DCR) based on investigator review per RECIST v1.1. and overall survival (OS). The association of patient's metabolism with 6-mont2021-01-01T00:00:00Z2021 Nov2026-05-08T00:44:35.079Z2022-02-11T12:21:49.375ZS-EPMC85365323468803010.1016/j.ebiom.2021.103630